102,436 research outputs found
Relevance of pharmacogenomics for developing countries in Europe : implementation in the Maltese population
No full textPharmacogenomics is a promising new discipline that can realize personalized treatment for patients suffering from many common diseases, particularly those with multiple treatment modalities. Recent advances in the deciphering of the human genome sequence and high throughput genotyping technology have led to the reduction of the overall genotyping costs and enabled the inclusion of genotype-related dosing recommendations into drug package inserts, hence allowing the integration of pharmacogenomics into clinical practice. Although, pharmacogenomics gradually assumes an integral part in mainstream medical practice in developed countries, many countries, particularly from the developing world, still do not have access either to the knowledge or the resources to individualize drug treatment. The PharmacoGenetics for Every Nation Initiative (PGENI) aims to fill in this gap, by making pharmacogenomics globally applicable, not only by defining population-specific pharmacogenomic marker frequency profiles and formulating country-specific recommendations for drug efficacy and safety but also by increasing general public and healthcare professionals’ awareness over pharmacogenomics and genomic medicine. This article highlights the PGENI activities in Europe and its implementation in the Maltese population, in an effort to make pharmacogenomics readily applicable in European healthcare systems.peer-reviewe
Method for the assessment of pharmacogenetic response to treatment with lithium salts in bipolar disorder
No full textReturns to investment in education : a further update
No full textReturns to investment in education based on human capital theory have been estimated since the late 1950s. In the 40-plus year history of estimates of returns to investment in education, there have been several reviews of the empirical results in attempts to establish patterns. Many more estimates from a wide variety of countries, including over time evidence, and estimates based on new econometric techniques, reaffirm the importance of human capital theory. The suthors review and present the latest estimates and patterns as found in the literature at the turn of the century. However, because the availability of rate of return estimates has grown exponentially, the authors include a new section on the need for selectivity in comparing returns to investment in education and establishing related patterns.Curriculum&Instruction,Teaching and Learning,Public Health Promotion,Decentralization,Economic Theory&Research,Agricultural Knowledge&Information Systems,Health Monitoring&Evaluation,Economics of Education
Individualizing clozapine and risperidone treatment for schizophrenia patients
No full textSchizophrenia is one of the most devastating mental and neuropsychiatric disorder that affects almost 1% of the population. It is usually diagnosed during adolescence and later on, symptoms like delusions, hallucinations, depression, etc, appear. Environmental and genetic factors play important role in the development of schizophrenia, but, causes leading to it are still unknown.
Clozapine is essentially the first drug that falls under the banner of the’atypical’ drugs and is effective both in positive as well as in negative symptoms and cognitive dissonance. Risperidone is another atypical antipsychotic which is effective against negative symptoms and seems to be the treatment of choice for newly diagnosed patients.
According to various studies, candidate gene variants are associated with clozapine's and risperidone's response; in particular, dopamine, serotonin glutamate receptor genes, hormone-related genes, neurotransmitter transporter genes and nucleotide binding protein genes.
Our aim was to put together current research concerning those two drugs. Moreover, our work allows the comparative study of polymorphisms in specific genes for two commonly used drugs for the individualization of treatment.
Pharmacogenetic studies of clozapine and risperidone in SZ have thus far provided incongruent findings. However, the recent significant improvements in pharmacogenomics approaches and available technologies may lead to the identification of clear-cut determinants which, if implemented in a framework of molecular and clinical information, would significantly contribute to the prediction of treatment response and prevention of Adverse Drug Reaction
J’Accuse….. Or The Plight of pro-bono Volunteer Scientists in Academic Publishing
No full text[Extract] The immortal words of Èmile Zola: “J’accuse…” were his introduction to a letter on the mistreatment of a French citizen [1]. We believe Springer Nature (and other commercial publishing houses) need to similarly clean up their acts in the area of pro-bono volunteer scientists and hence this melodramatic yet appropriate start to this letter
Bibliographie Hilarion G. Petzold 1958 – 2009 mit Anhang als Einführung
No full textDieses Archiv enthält die Gesamtbibliographie der Werke des Autors nebst einiger Texte „Über H. G. Petzold“ im Schlussteil der Bibliographie sowie einen Anhang mit einer Einführung in die Architektur des Werkes in seinem wissenslogischen Aufbau als Ausarbeitung seines „Tree of Science Modells“ (2007).This archive contains the complete bibliography of the author and some texts about H. G. Petzold, moreover an epilogue with an introduction to the architecture of the works in its epistemological structure and composition and as an elaborations of Petzold’s „Tree of Science Modell (2007).https://www.fpi-publikation.de/polyloge/01-2009-petzold-h-g-gesamtbibliographie-h-g-petzold-1958-2009-updating-november2009/peerReviewedpublishedVersio
Creating Transparent and Reproducible Pipelines:Best Practices for Tools, Data, and Workflow Management Systems
No full textA Review of Tools to Automatically Infer Chromosomal Positions From dbSNP and HGVS Genetic Variants
No full textDispelling the Myths Behind First-author Citation Counts
No full textWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
- …
